Good morning, welcome on our behalf as well. We are obviously in a good mood this morning. We have a very good quarter two report to present. Our companies have done a fantastic job during the quarter, so it's really great performance. If we start to look at some overall highlights, we can briefly comment on them. What really stands out, I would say, in the quarter is the strong demand, the strong order intake, the strong top line. We improve both sequentially versus Q1 and also versus Q2 in 2020. Really high numbers organically, +26% in order intake and +16% in sales. All of this we will comment on more in detail in a few slides. We obviously review our companies and business areas on a regular basis. It's recently been extremely green, I would say, on the KPI charts. Basically all companies and segment countries are in a positive situation, very few red dots on the charts. Some of our companies, quite a few of them are obviously having a bit of a stretched supply chain situation. We see higher raw material prices, higher component costs, and we also have issues with long lead times in terms of deliveries and also freight prices increasing and so on and so forth. You have heard about this from other companies already. I think our model with having entrepreneurial MDs and agile companies is managing this really in a good way. The overall impact financially on a group level is still limited. We had a record high EBITA margin, 15.2%, super strong for us. We are also improving our working capital efficiency, which we think is good. Obviously, the top line is increasing and improving the ratios, but we are actually managing the inventories and also receivables in a good way. We will comment more on that. We have made three acquisitions in the quarter and one now in the beginning of Q3. All in all, nine acquisitions, and plus SEK 700 million in top line on a yearly basis. Perhaps even more importantly, a good pipeline to work with. If we turn our eyes to the order intake slide. You see the bars on the slide, and the blue bar is obviously quarter two, and it's perhaps good to start reflecting on what happened in quarter two 2020. That's really when the pandemic hit more seriously in a general sense for a lot of businesses in a global perspective. Also for us, the order intake impact was, I would say, only 5% down in quarter two 2020. Some hits, but not very significant. That is an important reference to have when you look at the increase we have in this quarter, + 26% organically and 30% in total. In that perspective, I think very strong numbers. As I said before, it's really almost all companies and segments show a positive development. We have spoken a lot about the MedTech pharma segment in previous quarters that remains strong. Also infrastructure and process industries. Now we also see more of a recovering broader engineering sector, which is positive for a lot of our industrial component companies which we have in different countries. We have a large valve company in the Netherlands. They still have a good order intake situation, they had a very strong Q2 in 2020. Reference-wise, a little bit lower now, but still, I would say, a good situation. All business areas grow their orders organically during the quarter with double-digit growth numbers, and the strongest development was in DACH, in U.K., and in Fluids & Mechanical Solutions. Order intake was a positive book to bill, +8% higher than the sales. As I said, in total +30% order intake growth organically, +26% acquisitions added another +7%, and the currency worked against us with -3%. In order to understand the order intake situation, we have looked at the average daily orders and compare that with the situation in Q1. I would say on average we are 5% higher in Q2. Sequentially we are growing and having a good order intake situation in quarter two. There is an obvious question linked to pre-buy and order for inventory buildups. There is some of that, I'm sure. Definitely in the MedTech and pharma segment, I think the big global international pharma companies are really trying to buy ahead. There is also some pre-buy in the industrial segment. Still on an overall level for Indutrade, not very significant is our judgment. Turn page and look at net sales, it's also a very good situation, strong in the quarter, and we have definitely increased our backlog. Total net sales development was +20% versus last year, the organic development was +16%, acquisitions +7%, and currency again st us with -4%. In Q2 2020, organic sales was -5%, not super dramatic. +16% is again, a very strong number, I will say. In a geographical perspective, when we look at our larger countries, what stands out is obviously the U.K. and Germany. Finland and Switzerland have slightly lower growth rates, but they have really good references in 2020. Still, I would say a good situation also in those countries. As I said, the delivery issues, potential component shortages and things like this was not very significant. A rough estimate is that we had a negative effect of around 1%-2% lower sales during the quarter linked to this on a group basis. Perhaps this will intensify a little bit in quarter three versus quarter two. It's very difficult to judge, but perhaps a little bit even more issues in quarter three. Unsure how this will develop. We turn to our profitability development. It was, as I said, super strong. EBITA increased with 40%, which is very high numbers. The EBITA margin in itself was at an all-time high level at 15.2%, last year 13%. In addition to the portfolio companies we have held for some time, also the newly acquired companies is contributing in a strong and positive way. Organically, EBITA increased with 32% and acquisitions added 12% and currency was minus 4%. We obviously have a very strong leverage from our increased top line dropping down to the bottom line. There is still some utilization of programs for short time work at a handful of companies, but on an aggregated level, it's very limited, and the financial impact of governmental support in the result was therefore only 0.1% of sales. In Q2 last year it was 1.5%. The upward pressure on prices for raw materials and components continued in the quarter. I would say our companies have successfully really worked with proactive pricing to offset these increases in an incredibly good way. So far we don't really see a negative impact on our gross margin on an aggregated level. We actually improved our gross margins, which Patrik will elaborate on a little bit later on here. If we turn to our business area situation and look at organic sales growth for quarter two. As I said, our KPI charts are very green. Almost all companies and segments develop positively. You see on the bar diagrams here that the four business areas to the right there are actually increasing more than the four towards the left. They also all had a little bit different references from Q2 2020. The ones towards the right, those four had more difficult situations in 2020, and the ones to the left, Benelux had +12%, Finland and Flow was fairly stable, and DACH -7%. The strongest growth was in business area U.K. Most companies in the business area grew, but the growth was partially fueled by lower levels last year, -26%. The COVID-19 lockdown has probably been the hardest in that business area and country for us, and really had severe impact on both infrastructure and the construction businesses in Great Britain. If you look at Fluids & Mechanical Solutions, they had a strong sales situation driven by, for example, the automotive aftermarket and also some infrastructure-related companies. Industrial Components was driven by, again, good MedTech sales, but also more broadly in the engineering segment. In what we call MST, Measurement and Sensor Technology, standing out is the force sensor and instrument segments, but broadly good there as well. Flow Technology had also a good situation in MedTech and pharma. They had a very good situation last year in those segments. Not a super strong growth this year, but a very difficult reference. In Finland, I would say good development in the infrastructure segment and energy segments. In DACH, the Swiss pharma and process industries were positive. In Benelux, most of our companies developed very well. Our larger company for high-performance valves did well, but did extraordinarily well in Q2 last year. What other can we say? I would say some municipalities are actually delaying projects right now. They are hoping for lower project costs sometime in the future. Even if that is happening, we are still performing very well. I would say also some process industries, refineries and similar, are deferring their maintenance stops this summer to 2022 or even 2023. They are having so strong profitability right now, so they don't want to stop. They prefer to run. Again, even if we don't benefit from that, we still see very good numbers. If we look at the EBITA margin per business area, again, we came in on an overall all-time high level at 15.2%, and seven out of eight business areas increased their margins quite well, I would say. It's obviously the strong sales improved gross margins, which are driving the bottom line here with really good leverage. As I said before, also supported by good development in the newly acquired companies. It's broad-based. Maybe what needs to be commented here is the U.K. situation, where, as I said, a clear majority of the companies are growing, but we have a few companies with some segment issues, and they have high profitability, usually, but not right now. The company mix, product mix is hampering the U.K. profitability, and we also saw some one-off related costs in a few companies, which added to the situation with a fairly strong, stable profitability level at 12% there. I think U.K. will improve in H2 versus the level we see right now. Acquisitions, really, I would say a positive situation. We did 3 good acquisitions in the quarter. We acquired a Danish company called CKJ Steel, working with a MedTech segment in Denmark, and Denmark has a very large and growing MedTech market. We were very happy to be able to acquire CKJ Steel. We bought a smaller company called Lamisa, a sealing product company, a Swedish company with very high service level and a good niche position. We bought another Danish company called Buhl & Bønsøe, involved in measurement instruments and calibration in Denmark. High market share, strong market position. After the end of the quarter, we were able to acquire Atlas Industrial Print, working with industrial product marking solutions. A market we know well. We already own a company called Topflight in this segment. It's obviously a very good addition. Very happy with that. As I said before, the annual turnover level of all the acquisitions so far is a bit more than SEK 700 million. We have a lot of projects in different stages, and the pipeline has been good. It remains good. We also see that the level of incoming project is actually increasing a bit from quarter one and earlier. We have, however, experienced a slight price increase that is good profitability in a lot of companies now, and it's not unfeasible that prices go up. It's especially for what we call quality companies with good growth capabilities going forward. It's still manageable and I'm optimistic and positive in terms of acquisitions for the second half of the year as well. By that, I leave the word over to Patrik to comment on the financials in more detail. Thanks, Bo, hello, everyone. Let's dive into the numbers of the quarter. As Bo mentioned already, it was a fantastic demand level during the quarter, and we came in at +30% for orders and +20% for sales. That's really good. Year to date, we are now at +17% and +12%, respectively. Order intake was higher than invoicing, +8% in the quarter and +10% year to date. Order backlog is now, of course, very strong when we move into the second half of the year. Despite headwind from increased supplier prices, we managed to increase the gross margin during the quarter, and it was 34.8% versus 33.7% last year. Year to date, it's also higher than last year, 34.6% versus 33.9%. The increase comes mainly, I would say, from more favorable, better product mix, and also higher volumes in our manufacturing companies, giving us some good volume or cost absorption. All this was, of course, made possible through very good proactive pricing work by our companies offsetting the higher supplier prices. The main driver is, I would say, the mix and good cost absorption, I would say. EBITA grew 40% in the quarter and improved to the all-time high of 15.2%, a very strong number than versus 13% last year. Accumulated, we are now +28% and at the margin of 14.5% versus 12.7% last year. Finance net, slightly lower than last year, and that's mainly driven by lower debt levels. Tax costs up, of course, 45% in the quarter and 34% year-to-date, basically in line with the profit increase. Underlying tax rate is basically the same as last year. Earnings per share up 51% in the quarter and 34% year to date. Return on capital at 21% versus 18% last year. The increase is mainly driven by the higher result, but of course also supported somewhat by the increased working capital efficiency that we have. Operational cash really strong, continues to be really strong, but actually decreased slightly versus last year, and I will elaborate a little bit on the next slide. Net debt/EBITA continue on a low level thanks to the favorable result and cash flow development at 1.5x versus 1.8x last year. Let's move to look at the cash flow more in detail. As you can see then, cash flow was very strong and came in at almost SEK 800 million. The slight decrease versus last year due to an increase in the working capital, and that's mainly receivables. Last year, working capital decreased, and that's why we managed that high level last year. As I said before, we continue to improve the working capital efficiency and inventories were actually organically lower than the same quarter last year, which is, of course, good. Then moving to the next slide, looking at earnings per share. Q2 earnings per share grew with 51% from SEK 1.02 to SEK 1.54, which is a slightly higher increase than the EBITA increase. The main driver of the improvement is, of course, the EBITA improvement, but also supported by stable or lower amortizations of intangibles and also the finance net I mentioned before. Looking at the more longer-term perspective, three and five-year increase in the annual earnings per share were +16% and 15%. From that, moving on to the debt situation. The interest-bearing net debt end of the quarter increased slightly sequentially to SEK 5,389 million, and due to the dividend payout, I would say, in the quarter, so it's quite natural increase. On a more longer-term perspective, I would say the debt level is on a low level. The main reason for that is the good cash flow during both the end of last year and the beginning of this. Net debt equity ratio decreased to 59% from the 72% last year. A low level from a historical perspective, especially for a second quarter. Altogether, that makes our financial position remains very strong. During the quarter, we actually issued a new 5.5-y ear bond to shift part of the borrowing from short to long-term. I think the interest from different debt investors were really good, and I think we landed really competitive terms. Thanks, and I leave back to Bo. Good, Patrik. We take a look at our group management situation, which we have strengthened during the quarter. We work with an overall ambition labeled sustainable profitable growth and b elow that, it's obviously both developing our portfolio of companies we already own and then being very active in terms of an acquirer. If we stay at the portfolio we already have, we have a segment of companies working with the MedTech pharma businesses. A cluster of those companies have together formed an independent brand called UltraPure International, where we are a producer, you can say, more of an assembler. We assemble things in cleanroom environments, usually silicone tubing systems or sets. We now have a number of companies doing that. They work during that brand, UltraPure International. This is then sold via these companies and also by some additional trading companies we have. Some of these companies sell to the same type of very large customers, global international big pharma customers. These companies also buy from some of the same suppliers in terms of raw material. In order to develop and coordinate this business a bit, we have asked Morgan O'Brien, who was previously head of our Flow Technology business area, to enter into a role of broadly business development into this new segment for us. He has a lot of knowledge, experience, capability, contacts in this industry. He fits in extremely well here. He has entered into that role, and as I said, his role is more development oriented. The companies still belong to their respective business area, so this has no impact in terms of our reporting structure. Morgan left an open spot in the Flow Technology area, which we filled internally with Per-Olow Jansson. Per-Olow has been a very successful managing director for one of our Swedish flow companies called the GPA Flows ystems. He has also been a business unit leader chairing a handful of other companies. He knows the Indutrade culture and business model extremely well. It was a fairly seamless change from Morgan to Per-Olow. We were also able to internally find a successor to Per-Olow in that specific Swedish company, GPA Flows ystem also. Good that we can handle these management sort of appointments all internally with highly qualified persons. Obviously we have high hopes to continue to develop this MedTech pharma system business, and it's one of our stronger initiatives in terms of organic growth going forward. We've made one slide to try to simplify your work in terms of what are the effects of COVID-19 in quarter two for Indutrade. I think I have more or less commented on all of these already, but still doing them. We have some COVID-19 related orders, but they were substantially higher in quarter two 2020. We have some disturbances and disruptions supply chain-wise, but not very significant on the group level, as I said, perhaps impacting around 1%-2% of sales. We have discussed the raw material and component and freight situations. Short-time work declined further during the quarter, and the majority of the furloughs we have are in business area U.K. and they have been previously impacted on lockdowns. Our personnel-related governmental support was marginal and during the quarter amounted to 0.1%, and it was 1.5% in Q2 last year in relation to net sales. Basically, it all works well now. We have a company in Malaysia which can only run at 60% speed linked to some authority regulations there. We have some issues locally in South Africa. Also a company which can't operate linked to local authorities. We have had some smaller outbreaks in some European companies where it has some impact on operations for a week or so, but not more. All in all, I would say very manageable situation. We are at the key takeaways. Really strong and broad demand. Maybe that's the important word. Green chart of KPI numbers very broadly in the group, and record high EBITA margin, and also improved capital efficiency to things which are obviously very important to us. Nine acquisitions so far. Top line of plus SEK 700 million and a good, strong pipeline for the second half of the year. We have a very high order backlog. We see a stable demand situation into the fall here now. Positive outlook on the market, you can say. We definitely have some supply chain issues, but we think with the type of entrepreneurial and agile companies we have, it's still manageable. Very positive performance in quarter two and an optimistic outlook for the second half of the year as well. By that, we say thank you for listening in, and we open up for a Q&A session. Thank you. If you do wish to ask a question, please press zero one on your telephone keypad. If you wish to withdraw your question, you may do so by pressing zero two to cancel. Our first question comes from the line of Carl Ragnerstam from Nordea. Please go ahead. Hi, good morning. A couple of questions from my side. First of all, on the organic growth, you said that it's been fueled partly by pre-buying effects. I wonder if it's possible to quantify the pre-buying effects. I guess it might be a bit difficult, but if you could try. Also, if we should expect the pre-buying effect to continue when entering Q3 as well. We have a very difficult to set the number on the pre-buy effect, but it's not very material on a group level, I would say. I don't know, Patrik, if you want to elaborate on this number-wise? We've talked with our companies and business areas about it, and there are examples of it, but it's not very broad, those comments, I would say. Quantifying it, difficult. It's mostly MedTech and pharma related, and to some extent in the more industrial-oriented companies. It's definitely not in a majority of our companies we see it, not so. I think it will probably continue a little bit in quarter three as well. It's such strained supply chains now, so it's a clear business opportunity if you can deliver. I think some of that will probably continue. Okay, perfect. Also, it doesn't sound like a big problem during Q2, but on the raw material side, maybe attached upon it, but you mentioned that some subsidiaries were impacted, but you implement the price increases. Should we assume a slightly bigger impact in the coming quarters as raw material prices usually comes with a bit of a lag? I think that's a good assumption. Cautiously, a little bit more difficult in Q3 than Q2 will be my assumption. Okay, perfect. On the cost side, you talked for a while about ramping up costs. Could you give us some flavor on it? What magnitude and where do you see that you need to ramp up cost? Also if we should see or expect to see cost ramp up already in Q3 related to selling marketing expenses? It's for the most part top-line related cost increases down. You need a little bit more headcount to deliver or operationally handle a higher top line. We try to have a portfolio perspective in each of our business areas and those companies with clear organic growth opportunities, we really want to support them and they should go for growth. If they need headcount increases they should appoint those persons. Some of the companies have a little bit less organic growth opportunity short-term, and there we should manage cost a bit more closely. I think we as a group and definitely the individual companies are handling this in a strong way. I'm not really worried about the cost in a ratio versus sales perspective. I think this will be managed well. Anything more, Patrik, from your side? No, maybe that if market sales activities have, during quarter two, increased slightly, but I would say they are still on a relatively low levels, and we've had restrictions for most part of the quarter. If, when societies open up even more, I would say that these type of activities even in the new normal will increase in many companies. It's not a major increase, but it will impact the cost level, of course. You will probably see a bit of a travel bump. As Patrik says, we discussed the new normal with our companies, and they all should have a plan for that. They all will obviously try to actually physically visit customers whenever they can. If you haven't done that for a year or a year and a half, it's obviously important to do that. I think quite a lot of companies, when they can, they will travel more to visit customers. They will not continue to visit customers physically in the same way as they did before the pandemic. It's going to be much more of a mixture between digital and physical meetings. I don't know if it's going to be in quarter three or quarter four, but in any of those quarters there will be a little bit of a travel bump t hat I expect. Okay, perfect. The final one from my side in terms of M&A, maybe also a difficult question, but we have seen quite nice M&A pace both for you as well as the sector year to date. Would you say that it is that you're working through a catch-up effect given the restrictions during the pandemic, or would you say that more companies won't sell their business? Also if you want to comment on the increasing multiples, if you could quantify or give an example. It's not a very significant sort of catch-up effect. We still did what, 10 acquisitions last year. It was a fairly good level, even if we had a pandemic. It's a positive market. It's definitely more incoming projects than two, three quarters ago. As I said, the pipeline is good. All business areas are engaged in different projects. It's a quite broad sort of positive situation. It's going to be simpler and easier now when it's less restrictions in terms of meetings and travel to visit the companies. It's, I think, a positive situation. Prices are going up a bit, mostly I would say in Scandinavia, Nordics, perhaps predominantly Sweden, but it's still manageable. We have said no in some projects, quite few though, but we have done that. We know what levels we want to buy at, and we know exactly what we are looking for and so on. We are fortunate enough to have been doing this for 41 years, so we are fairly established, I would say, and the incoming sort of projects is, I would say, at a higher rate for us than in many lesser established companies in this field. Do you want to add anything, Patrik, or? No. Not really. Okay, perfect. Thank you. Thank you. The next question comes from the line of Robert Redin from Carnegie. Please go ahead. Yeah. Hi. I just wanted to ask on that very strong order intake in the quarter. If the lead time or delivery time on those orders is sort of longer than normal, if you expect to see less of that in Q3 than a normal pattern? In our MedTech and pharma business, we are reaching some capacity issues in these cleanroom assembly units we spoke about. There we have had a little bit longer delivery lead times out from us. If we expect or if we sort of take out that part, I think it's fairly normal. You can add here, Patrik, also, if you want. I think there's a slight increase, but I don't think it's not material if you exclude the MedTech pharma sector, which you mentioned, Bo. A slight increase, I guess, but that's more of a gut feeling rather than something I can quantify. All right. That sounds great. You mentioned those costs in the U.K. of sort of non-recurring nature, but how small were they? Could you say something about the magnitude? You'll to take that? Yeah. In total, they were, say, around SEK 5 million. Okay. In a handful of companies. Right. Okay, perfect. Thanks so much. That's my questions. Thanks. As there are no further audio questions, I'll hand it back to the speakers. We say thank you for listening in, participating, and wish you all a good summer, and we keep in touch. Bye-bye from us.